New solutions in the fight against advanced prostate cancer
Scientists have tried for a cure for advanced prostate cancer or at least to find solutions to the consequences of the disease to slow down. So, have a vaccine that seems to enhance the immune response to fight prostate cancer. The vaccine is still in clinical trials to test its full efficiency, in order to adjust the dosage and if it works with less advanced prostate cancer to see.
Eric J. Klein, MD, UCSF professor of medicine and urology, along with 19 other institutions in the U.S. study, which was funded by Dendreon Corporation (vaccine development), based in Seattle, Washington. They tested 31 patients suffering from metastatic asymptomatic hormone refractory prostate cancer (HRPC) and was only one years old. The study was designed to see if disease progression is delayed and the patients survive longer. July1 2006 in the Journal of Clinical Oncology has published the first findings of this study.
After two months of treatment prov England, 20 patients developed an immunity to a reactive protein on the cell surface of the prostate (prostatic acid phosphatase). In these patients, the disease has progressed after 34 weeks, but in the case of the remaining 11 patients the disease after 13 weeks.
The vaccine was well tolerated by patients and adverse events were mild fever and chills. Five of the subjects reported mild urinary problems. This is good news because the chemotherapy makes many unacceptable side effects.
The vaccine is made from a protein and a genetically dendritic cells through the blood of the patient.
TJ Koerner, PhD, director of the scientific program of the American Cancer Society (ACS) said the vaccine is still under experimentation, because the dose must be adjusted and the combination of drugs should be tried. In addition, scientists want to see if this vaccine is less advanced prostate cancer. Until now, researchers do not know what are the consequences of prolonged treatment with this vaccine to patients.
In the U.S., prostate cancer is common and more than 200,000 new cases detected each year. Most patients can follow a treatment based on surgery, radiotherapy and hormone therapy, but asymptomatic metastatic HRPC is known to be resistant to hormonal therapy and each year more than 30,000 people die because there is no other treatment is effective against the disease is This is because a treatment is urgent.
For more information about the early symptoms of prostate cancer and prostate cancer symptoms please visit this site http://www. prostate cancer center. com
-Recent Articles on NET-
Popularity: 1%
